Chassain C, Eschalier A, Durif F
Unité INSERM EMI 9904, Faculté de Médecine et Pharmacie, 28, place Henri-Dunant, 63001, Clermont-Ferrand, France.
Exp Neurol. 2003 Aug;182(2):490-6. doi: 10.1016/s0014-4886(03)00125-0.
The antiparkinsonian action of an NMDA receptor antagonist, magnesium sulfate (50, 100, and 200 mg/kg), alone and in association with levodopa was explored in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian and control rhesus monkeys. At the three doses tested, magnesium sulfate decreased levodopa-induced dyskinesia [cumulative dyskinetic scores after levodopa: 129 +/- 13; after levodopa and magnesium sulfate: 65 +/- 14 (50 mg/kg), P < 0.001; 64 +/- 10 (100 mg/kg), P < 0.001; 66 +/- 21 (200 mg/kg), P < 0.001, compared to levodopa administration alone]. These results show that magnesium sulfate importantly reduces levodopa-induced dyskinesia.
在1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）损伤的帕金森病恒河猴和对照恒河猴中，研究了N-甲基-D-天冬氨酸（NMDA）受体拮抗剂硫酸镁（50、100和200mg/kg）单独及与左旋多巴联合使用时的抗帕金森病作用。在测试的三个剂量下，硫酸镁均可减轻左旋多巴诱导的异动症[左旋多巴给药后的累积异动症评分：129±13；左旋多巴和硫酸镁给药后：65±14（50mg/kg），P<0.001；64±10（100mg/kg），P<0.001；66±21（200mg/kg），P<0.001，与单独给予左旋多巴相比]。这些结果表明，硫酸镁可显著减轻左旋多巴诱导的异动症。
